Myriad genetics®

Sam Raha
PRESIDENT AND CEO

JANUARY 14, 2026

JP MORGAN 46th ANNUAL HEALTHCARE CONFERENCE

Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

The Company is in the process of finalizing its financial results for the quarter and full year ended December 31, 2025, and the financial guidance, data, and other information for the quarter and full year ended December 31, 2025 in this presentation is based on available information to date and is derived from preliminary, unaudited internal financial reports. This preliminary, unaudited financial information and data may change in connection with the finalization of the Company's year-end closing and reporting processes and financial statements for the quarter and full year ended December 31, 2025, and therefore, the financial guidance, data, and other information for the quarter and full year ended December 31, 2025 in this presentation may not represent the Company's actual financial results for the quarter and full year ended December 31, 2025.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business.

The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted at the time of this presentation. Such adjustments include, but are not limited to, strategic realignment, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.

We advance health and well-being for all, by providing testing solutions that enable healthcare providers to better prevent, detect, and treat disease

Leveraging our strengths to chart the future of the new Myriad

Leader
in Molecular Diagnostic testing and Precision Medicine

1,000+
scientific publications

55K+
healthcare providers served in 2025[1]

1.5M+
patient tests reported in 2025

Strengths

Reputation based on quality and science

Sample processing and reporting operational excellence

Commercial coverage and customer relationships

Reimbursement engine

Going forward

Focused investments

Cancer Care Continuum portfolio

Strategic partnerships

Right team

Execution excellence

Expanded AI leverage

1. Total number of providers having placed an order in 2025

Myriad's strategic direction

Driving accelerated growth and profitability by focusing on the Cancer Care Continuum and strengthening execution

Cancer Care Continuum
Accelerate growth with new products and expansion into attractive applications

Healthcare Screening
Drive Prenatal Health and Mental Health growth at or above market

Execution Excellence
Maintain disciplined focus on execution and sustained profitability

Serving multiple large attractive markets

	Precision Oncology				Risk and Screening		
	AFFECTED HCT[1]	PROSTATE BIOMARKER	THERAPY SELECTION; HRD & CGP[2]	MRD[3]	UNAFFECTED HCT	PRENATAL HEALTH	MENTAL HEALTH
TAM ($Billions)	$2	$1	$8	$21	$5	$3	$2
Est. Annual Market Growth	7-10%	12-15%	14-17%	15-20%	9-12%	2-5%	2-5%
Top 3 Market Position	▲	▲	▲ Reflects position in HRD market only		▲		▲
Planned New Products	▲	▲	▲	▲	▲	▲	

Plan to leverage market leading positions and new products to accelerate growth

1. Hereditary Cancer Testing
2. Homologous Recombination Deficiency and Comprehensive Genomic Profiling
3. Molecular Residual Disease

Sources: Definitive Healthcare 2024 Claims Data, Competitor earnings reports, 2025 Awareness, Trial, Usage Primary Market Research, ACS Cancer Facts & Figures 2025, GlobalData Epidemiology Database, Clarify 22/23 Claims Data, equity research reports, and Internal Estimates

Expanding testing menu to serve more of the Cancer Care Continuum

Hereditary cancer or multi-cancer early detection screening — Germline screening — Germline screening and tumor profiling — Tumor profiling and CDx testing — Molecular Residual Disease testing — Tumor profiling and CDx testing — Molecular Residual Disease monitoring

Risk & Early Detection	Diagnosis & Therapy Selection	Monitoring & Therapy Adjustment	Remission
MyRisk® Hereditary Cancer Test with **RiskScore®**	MyChoice® CDx Myriad HRD Companion Diagnostic Test	MyChoice® CDx Myriad HRD Companion Diagnostic Test	Precise® MRD[1] Molecular Residual Disease Monitoring
	MyRisk® Hereditary Cancer Test	Precise Tumor® Molecular Profile Test	
	Precise Tumor® Molecular Profile Test	EndoPredict® Breast Cancer Prognostic Test	
	EndoPredict® Breast Cancer Prognostic Test	Precise® MRD[1] Molecular Residual Disease Monitoring	
	Prolaris® +AI[1] Prostate Cancer Prognostic Test	Myriad genetics® | MSK ACCESS[2] SOPHiA DDM™	
	Myriad genetics® | MSK ACCESS[2] SOPHiA DDM™		

1. Target launch H1 '26
2. Available for pharma use

Cancer Care Continuum Portfolio Update

Accelerating growth and gaining share in Hereditary Cancer

MARKET DRIVERS

32% of women 25 or older meet criteria for HCT and 53% of these see change in medical management[1,2]

Guideline expansion and increasing clinical adoption



Incorporates all genes strongly recommended in NCCN and ASCO guidelines

HIGHLIGHTS

- Launched MyRisk expanded panel; Q4 ’25
- Launch Disease Specific Panels; H1 ’26E
- Expand Breast Cancer RiskScore to 365 SNPs[3]; H2 ’26E
- Increase unaffected market activation

MyRisk expected to be a cornerstone of growth and profitability going forward

1. Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023;20(9):902-914. doi:10.1016/j.jacr.2023.04.002
2. https://pubmed.ncbi.nlm.nih.gov/36906849/
3. Single-nucleotide polymorphisms

Expanding offerings for Therapy Selection

MARKET DRIVER

Growing number of targeted therapies across cancer types are tied to therapy selection tests



HIGHLIGHTS

- Expand HRD indications
- Expand IHC[2] offerings to complement Precise Tumor
- Sophia Genetics / MSK partnership provides liquid biopsy CGP assay for Biopharma; option for clinical test

Building towards a comprehensive Therapy Selection portfolio to support Precision Oncology

1. Available for pharma use
2. Immuno-histochemistry

Advancing prostate cancer testing with molecular and AI capabilities

MARKET DRIVERS

1 in 8 men in the US develop prostate cancer[1]

3M+ prostate cancer survivors



Prolaris® +AI

Prostate Cancer Prognostic Test

LOWER SCORE ⟷ HIGHER SCORE

Active surveillance	Single-modal treatment	Multi-modal treatment

Partnership with PATHOMIQ

With over 60% of low-risk patients on Active Surveillance,[2] AI tools have potential to more effectively guide clinical decisions

HIGHLIGHTS

- Launch first AI-enhanced Prolaris; H1 '26E
- Launch of second AI-enhanced Prolaris test planned for 2027
- Plan to progress clinical programs to strengthen NCCN guideline position

Uniquely positioned to deliver molecular + AI profiling, CGP and germline testing for prostate cancer care

1. National Cancer Institute (https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html)
2. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801916#google_vignette

Entering MRD market with a differentiated approach

MARKET DRIVERS

Growing market awareness of the importance of ultra-sensitive detection

Community oncologist preference for comprehensive offering

HIGHLIGHTS

- Compliments Myriad's portfolio of tests across the Cancer Care Continuum
- Deploying dedicated MRD sales team targeting surgeons and oncologists
- Numerous prospective and retrospective studies and publications underway

MOLECULAR RESIDUAL DISEASE TOTAL

TAM **$21B**

EST. ANNUAL MARKET GROWTH **15-20%**

MRD INDICATIONS

	BREAST	CRC[1]	RENAL	OVARIAN & ENDOMETRIAL
TAM	$7B	$5B	$1B	$2B

Precise MRD is an ultra-sensitive, tissue informed assay that can detect ctDNA down to 1 part-per-million, enabling more confident clinical decision-making

The combination of test performance, comprehensive portfolio, and leadership in community medicine will enable Myriad to grow a leading MRD business

Growing MRD business through disciplined, phased launches

PRECISE MRD FOR BREAST CANCER

- Start clinical testing for select customers; H1 ’26E
- Submit for MolDx review and launch early access; Q3 ’26E
- Launch commercially; H1 ’27E

TRACKING EARLY PROGRESS

- Medical Oncologist and Breast Surgeon experience
- Targeted test volume and repeat orders

PRECISE MRD ROADMAP BEYOND BREAST

2026E

- Renal cancer MolDx submission and early access launch; H2
- CRC MolDx submission and early access launch; H2

2027E

- Renal cancer commercial launch
- CRC commercial launch
- Endometrial cancer MolDx submission
- Ovarian cancer MolDx submission



Prenatal Health and Mental Health Update

Expanding the Prenatal Heath market with FirstGene

MARKET DRIVERS

Only 50% of US providers utilize carrier screening[1]

Only 30% of fathers get screened when mother is carrier[2]



Non-Invasive Prenatal Screening
Carrier screening
Fetal recessive status
Blood compatibility
Starting at 8-wk gestational age*

HIGHLIGHTS

- Encouraging early access experience for FirstGene
- CONNECTOR study early results; H2 ‘26E
- Commercial launch; H2 ’26E
- Focused Prenatal Health sales team to deploy in H1 ’26

Commercializing FirstGene expected to be a growth catalyst for Myriad

* Estimated to begin in H2 ‘26

1. Pereira et al, J Assist Reprod Genetics 2019 Apr; 36(4): 709-716
2. Arjunan et al, Prenat. Diagn. 2021 Jun; 41(7):896-90

Leading Mental Health testing with disciplined focus and execution

MARKET DRIVERS

1 in 5 Americans develop a major depressive disorder in their lifetime[1]

Positive biomarker testing coverage continues as 23 states have enacted legislation[2]



Provided over 3 million tests to date from 37,000+ providers

2025 published study showed those with major depressive disorder had fewer psychiatric hospitalizations after taking the GeneSight test[3]

HIGHLIGHTS

- Focus on high growth accounts
- Leverage biomarker law momentum
- Leverage digital engagement
- Optimize direct-payment options

Genesight expected to achieve profitability over next few years with MSD growth and planned COGS reductions

1 Mojtabai R, et al. J Clin Psychiatry. 2008 Jul;69(7):106574
2 https://www.fightcancer.org/what-we-do/access-biomarker-testing
3.https://journals.lww.com/psychopharmacology/fulltext/2025/07000/real_world_impact_of_pharmacogenomic_testing_on.3.aspx

Financial Update

Preliminary Q4 and FY 2025 revenue

All figures in millions, except percentages

	Q4 2025E	2025E
Total Revenue	$207 - $209	$822 - $824

2025 COMMENTARY

Total test volume growth of approximately 1% YOY reflecting:

7%	6%	(4)%
Hereditary Cancer	Mental Health	Prenatal Health

Taking actions designed to drive strategic growth

Investing in the Cancer Care Continuum

Focus on driving commercial success

>$35M

expected investment in commercial over the coming years

- **Expansion of commercial organization**
  Meaningful increase in field sales team
- **Strengthen Sales Enablement**
  Increase tools to support product launches, increase market activation spend
- **Increase funding for strategic R&D programs**
  Clinical studies for MRD and other select tests

Introducing 2026 guidance and bridge to long range growth target

All figures in millions except percentages

	2026 FINANCIAL GUIDANCE	2026 COMMENTS
Total Revenue	**$860 - 880**	The mid-point of the 2026 revenue guidance range reflects an increase of approximately 6% compared to the mid-point of the preliminary 2025 revenue range.
Adjusted Gross Margin*	**68% - 69%**	This range incorporates the anticipated impact from new product launches
Adjusted EBITDA*	**$37 - 49**	The mid-point of the adjusted EBITDA range is expected to grow approximately 43% over the mid-point of the previous full year 2025 guidance range

Assumes currency rates as of January 14, 2026

* The company does not forecast GAAP gross margin and GAAP earnings before interest, tax, depreciation, or amortization (EBITDA) because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation.

Total Revenue

All figures in millions



Catalysts to watch in 2026E

HCT

- Launch of MyRisk Disease Specific Panels; H1
- Increase sample volume growth rate

Prostate Cancer

- Launch Prolaris AI test; H1
- Prolaris meta-analysis publication; H2

MRD

- Initiate clinical testing for select customers; H1
- MolDx submissions for Breast (Q3), Renal and CRC (H2)
- Breast publication, MONITOR study; H2
- CRC data as part of pan-cancer publication, MONSTAR3 study; H2

Prenatal Health

- Report out on FirstGene CONNECTOR study; H1
- Commercial launch of FirstGene; H2

Cancer Care Continuum

- Increase sample volume growth
- New strategic partnerships

New Myriad is set to deliver profitable accelerated growth

1. Prioritized focus on the Cancer Care Continuum; Myriad has a right to win
2. Robust new product pipeline and strategic partnerships to address high growth markets
3. Extending commercial reach and leveraging operational strength
4. Leadership team with domain knowledge and proven experience
5. Strengthening execution excellence

Annual revenue growth expected to accelerate to HSD to LDD% (long-term target)

Q&A